Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

被引：0
|
作者：
Fei Liang
Sheng Zhang
Qin Wang
Wenfeng Li
机构：
[1] Fudan University,Medical Oncology, Shanghai Cancer Center
[2] Zhongshan Hospital,Department of Biostatistics
[3] Fudan University,Department of Medical oncology
[4] Shanghai University of Engineering Science,undefined
[5] the affiliated hospital of Qingdao University,undefined
来源：
BMC Cancer | / 20卷
关键词：
Randomized trials; Clinical benefits; Immune checkpoint inhibitors; Cancer; Food and drug administration agency;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
    Liang, Fei
    Zhang, Sheng
    Wang, Qin
    Li, Wenfeng
    [J]. BMC CANCER, 2020, 20 (01)
  • [2] Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Tibau, Ariadna
    Molto, Consolacion
    Ocana, Alberto
    Templeton, Arnoud J.
    Del Carpio, Luis P.
    Del Paggio, Joseph C.
    Barnadas, Agusti
    Booth, Christopher M.
    Amir, Eitan
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05) : 486 - 492
  • [3] RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Cherny, Nathan I.
    Dafni, Urani
    Bogaerts, Jan
    Latino, Nicola J.
    Pentheroudakis, George
    Douillard, Jean-Yves
    Tabernero, Josep
    Zielinski, Christoph
    Piccart, Martine J.
    de Vries, Elisabeth G. E.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (10)
  • [4] Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
    Molto, Consolacion
    Hwang, Thomas J.
    Borrell, Maria
    Andres, Marta
    Gich, Ignasi
    Barnadas, Agusti
    Amir, Eitan
    Kesselheim, Aaron S.
    Tibau, Ariadna
    [J]. CANCER, 2020, 126 (19) : 4390 - 4399
  • [5] RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Response
    Pierce, John P.
    Leas, Eric C.
    Benmarhnia, Tarik
    Strong, David R.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (10)
  • [6] Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis
    Fallah, Jaleh
    Gittleman, Haley
    Weinstock, Chana
    Chang, Elaine
    Agrawal, Sundeep
    Tang, Shenghui
    Pazdur, Richard
    Kluetz, Paul G.
    Suzman, Daniel L.
    Amiri-Kordestani, Laleh
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (07): : 1043 - 1050
  • [7] Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the US Food and Drug Administration Adverse Event Reporting System
    Raschi, Emanuel
    Antonazzo, Ippazio Cosimo
    La Placa, Michelangelo
    Ardizzoni, Andrea
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    [J]. ONCOLOGIST, 2019, 24 (11): : E1228 - E1231
  • [8] Reporting of immune-related adverse events (irAEs) in US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
    Tapiavala, Shaili
    Shenouda, Mina A.
    Patel, Vaibhav G.
    Davis, Andrew A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials
    Tibau, Ariadna
    Molto, Consolacion
    Borrell, Maria
    Del Paggio, Joseph C.
    Barnadas, Agusti
    Booth, Christopher M.
    Amir, Eitan
    [J]. JAMA ONCOLOGY, 2018, 4 (11) : 1610 - 1611
  • [10] Clinical benefit of breast cancer drugs approved by the United States Food and Drug Administration
    Carlos Tapia, J.
    Molto, Consolacion
    Bujosa, Aida
    Templeton, Arnoud J.
    Barnadas, Agusti
    Amir, Eithan
    Tibau, Ariadna
    [J]. CANCER RESEARCH, 2020, 80 (04)
12345